The 2nd International Conference on Drug Discovery & Therapy: Dubai, February 1 - 4, 2010


Session Speaker

Assessing the Degree of Success for Attaining Clinical Goals Among People Living with Diabetes in a Nigerian Teaching Hospital
Alebiosu C.O, Obi O, Ogunsemi O, Raimi T.H, Odusan O and A.E.A Jaiyesimi
Nigeria

Background: The American Diabetes Association (ADA) published treatment goals for physicians managing patients with diabetes mellitus in an attempt to improve control of diabetes and prevent complications. The success with which physicians are able to meet the clinical goals is unknown in Nigeria.

Objective: The study aim to assess the success with which physicians are able to meet the set ADA clinical goals in Nigeria.

Methods: Hospital records of sub-samples of consecutive patients with type-2 diabetes seen over 24months were reviewed to assess the attainment of the six ADA treatment goals and the frequency of receiving the four ADA-recommended health services. Results: The mean number of ADA goals attained was 4.4 +1.2. No patient had attained all 10 goals. A total of 118 (54.1%) and 123(56.4%) patients had attained the ADA goals of diabetes daily use of aspirin and HDL level respectively; most patients had attained ADA goals for triglycerides 189(86.7%), LDL level 168(77.1%) and diastolic blood pressure control 175(80.3). Most patients had not received annual eye examination 210 (96.3%) nor attained systolic blood pressure control 133 (61%). Although most of the patients had urinary microalbumin screening as part of another study protocol using the same sample population, routine urine microalbuminuria screening is not presently done and should be incorporated into the management protocols of our diabetics.

Conclusion: ADA treatment goals may be quite difficult to attain in the developing health care setting. Physicians and patients should make efforts to attain the ADA treatment goals so as to prevent diabetic complications.


















[Webmaster]   Copyright © 2010 2nd International Conference on Drug Design & Therapy